Pergolide Mesylate (Prascend)

Pergolide mesylate, marketed under the veterinary brand name Prascend, is the gold standard treatment for Pituitary Pars Intermedia Dysfunction (PPID) in horses, commonly referred to as equine Cushing's disease. This FDA-approved veterinary medication has revolutionized the management of PPID since its introduction, providing affected horses with improved quality of life, reduced clinical signs, and in many cases, years of additional productive life. As the only medication approved by the FDA specifically for the treatment of PPID in horses, Prascend represents the first-line therapy recommended by veterinary endocrinologists and equine practitioners worldwide.

The mechanism of action of pergolide involves agonism of dopamine receptors, particularly D2 receptors, in the pituitary gland. In healthy horses, dopamine produced by the hypothalamus naturally inhibits the activity of the pars intermedia region of the pituitary gland. In horses with PPID, the neurons producing this inhibitory dopamine undergo progressive degeneration, leading to loss of normal regulatory control and subsequent overactivity of the pars intermedia. This results in excessive production of hormones including adrenocorticotropic hormone (ACTH) and related peptides derived from proopiomelanocortin (POMC). By mimicking the effect of the missing dopamine, pergolide helps restore normal inhibitory control and reduces the excessive hormone production that causes the clinical signs of PPID.

Prascend is available as small, scored tablets containing 1 mg of pergolide mesylate, designed for once-daily oral administration to horses. The scored tablet design allows for dose adjustment in 0.5 mg increments, accommodating the range of doses that different horses may require for optimal disease control. Many horses readily accept the tablets when placed in a small treat or carrier food, though some owners prefer to dissolve them in a small amount of water for syringe administration. The relatively small tablet size and once-daily dosing make long-term treatment practical for most horse owners and caretakers.

While pergolide effectively controls the clinical signs of PPID in most horses, it is important to understand that this treatment manages rather than cures the underlying condition. The neurodegenerative process affecting the hypothalamic-pituitary axis continues despite treatment, meaning that most horses require ongoing therapy for the remainder of their lives. Dose adjustments are commonly needed over time as the disease progresses, and regular monitoring helps ensure that treatment remains optimized for each individual horse's needs.

The primary and FDA-approved indication for pergolide mesylate in horses is the treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction. PPID is a progressive neurodegenerative condition primarily affecting horses over 15 years of age, though it can occur in younger animals as well. The condition results in a constellation of clinical signs that significantly impact quality of life and can predispose affected horses to life-threatening complications, making effective treatment essential for maintaining welfare and longevity.

Hirsutism, the development of an abnormally long, wavy, and often curly hair coat that fails to shed normally, is perhaps the most recognizable sign of PPID and responds well to pergolide treatment. Many owners report significant improvement in coat quality within months of starting therapy, with affected horses developing more normal seasonal shedding patterns and shorter, healthier hair coats. This improvement is not merely cosmetic—the abnormal coat interferes with thermoregulation and creates a warm, moist environment that promotes skin infections, so treatment provides functional as well as aesthetic benefits.

Laminitis prevention and management represents one of the most important reasons to treat PPID with pergolide. Horses with uncontrolled PPID have significantly elevated risk of developing laminitis, a painful and potentially devastating condition affecting the laminae that attach the coffin bone to the hoof wall. The hormonal dysregulation associated with PPID, particularly elevated cortisol and insulin levels, predisposes to laminitis through multiple mechanisms. Studies have demonstrated that pergolide treatment reduces the frequency and severity of laminitis episodes in affected horses, making this medication potentially hoof-saving and life-saving for many animals.

Muscle wasting and loss of topline, common features of PPID, often improve with pergolide therapy as hormonal imbalances are corrected. The excessive cortisol-like effects in PPID promote protein catabolism and muscle breakdown, leading to the characteristic appearance of horses with potbellies and pronounced spinal prominence despite adequate nutrition. By reducing the hormonal excess driving this catabolic state, pergolide allows many horses to rebuild muscle mass and regain more normal body condition when combined with appropriate nutrition and exercise.

Immunosuppression associated with PPID makes affected horses prone to infections including sinusitis, tooth root abscesses, skin infections, and sole abscesses. By reducing the excessive hormone production that impairs immune function, pergolide treatment helps restore more normal immune competence and reduces the frequency and severity of these secondary infections. This improvement in immune function contributes significantly to quality of life and reduces veterinary costs associated with treating recurrent infections in PPID horses.

The FDA-approved starting dose for Prascend in horses is 2 micrograms per kilogram of body weight administered orally once daily, which corresponds to one 1-mg tablet per 500 kg (approximately 1,100 lb) horse. This conservative starting dose helps identify horses that may be sensitive to pergolide while initiating therapeutic effect. For most horses, this starting dose is insufficient for complete disease control, and dose escalation based on clinical response and laboratory monitoring is expected as part of the normal treatment protocol.

Dose titration is a critical component of pergolide therapy, as individual horses vary substantially in their response to treatment and their requirements for optimal disease control. After initiating therapy at the starting dose, veterinarians typically recommend reassessment in 4 to 6 weeks, including repeat measurement of ACTH levels and evaluation of clinical signs. Based on this assessment, the dose may be increased in increments of 0.5 mg (half a tablet) until clinical signs are controlled and ACTH levels fall within or near the target range. Some horses require 2 mg, 3 mg, or occasionally higher doses to achieve adequate control.

Administration of Prascend tablets can be accomplished through several methods depending on individual horse preferences and owner convenience. Many horses accept tablets placed directly in a small piece of apple, carrot, or other treat. Others do better when tablets are dissolved in a small amount of water (approximately 5 mL) and administered using an oral dosing syringe. Some owners crush the tablets and mix with a small amount of molasses or applesauce for top-dressing on grain. The key is consistency—using the same administration method daily helps ensure reliable dosing and allows for accurate assessment of treatment response.

Timing of administration should be consistent from day to day, though the specific time is flexible based on management routines. Most owners find that morning feeding time provides a convenient and memorable occasion for daily dosing, though evening administration works equally well if this better fits the barn schedule. What matters most is that the horse receives its dose at approximately the same time each day, every day, to maintain consistent blood levels of the medication.

If a dose is missed, administer it as soon as you remember unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed administration. Occasional missed doses are unlikely to cause immediate problems, but consistent daily dosing is important for optimal disease control. If doses are frequently missed, consider whether a different administration method or time might improve compliance, and discuss the situation with your veterinarian.

Treatment with pergolide is lifelong for horses with PPID, as the underlying condition is progressive and incurable. Stopping treatment results in return of clinical signs, often within weeks to months. Regular monitoring—typically every 6 to 12 months for stable patients, more frequently during dose adjustments—helps ensure ongoing optimal control and allows for dose increases as the disease progresses over time.

Pergolide is generally well tolerated by most horses, with the majority experiencing no significant adverse effects when appropriately dosed. The FDA approval process for Prascend included safety studies demonstrating an acceptable side effect profile at recommended doses, and post-market surveillance has confirmed this generally favorable safety record. However, as with any medication, some horses do experience adverse effects, and owners should be familiar with potential problems to enable early recognition and appropriate response.

The most commonly reported side effect of pergolide is temporary decrease in appetite, which occurs in a meaningful percentage of horses when treatment is initiated or when doses are increased. This effect is typically mild and transient, resolving within a few days to two weeks as the horse adjusts to the medication. Starting at the recommended low dose and increasing gradually helps minimize this effect. If appetite suppression is pronounced or persistent, temporary dose reduction followed by slower re-escalation often allows continuation of treatment.

Lethargy and mild depression are sometimes observed when starting pergolide or increasing doses, likely related to the medication's effects on dopaminergic pathways in the brain. As with appetite changes, these effects are usually temporary and resolve with continued treatment. However, horses showing significant or persistent depression should be evaluated to ensure that the symptoms are medication-related rather than indicative of disease progression or other health problems.

Gastrointestinal effects including mild colic signs, diarrhea, or changes in manure consistency have been reported in some horses receiving pergolide. These effects are generally uncommon and mild, resolving without specific treatment. However, any horse showing signs of colic requires evaluation to determine the cause, as horses with PPID are at risk for various conditions that could cause abdominal discomfort unrelated to pergolide treatment.

Rare side effects reported in horses receiving pergolide include sweating, anxiety, and behavioral changes. Very rarely, horses may show signs of ergot toxicity at high doses, including lameness or circulatory problems, though this is extremely uncommon at therapeutic doses. Any unusual symptoms developing after starting or adjusting pergolide should be reported to your veterinarian, as individual horses may have idiosyncratic reactions requiring dose adjustment or alternative management approaches.

Known hypersensitivity to pergolide mesylate or other ergot derivatives represents an absolute contraindication to Prascend use. While true allergic reactions to pergolide are rare in horses, any animal that has shown signs of hypersensitivity to this medication or related compounds should not receive pergolide again without careful veterinary assessment of the risk-benefit ratio. Signs of hypersensitivity may include hives, facial swelling, difficulty breathing, or severe adverse reactions following administration.

Horses with severe cardiovascular disease may require careful evaluation before starting pergolide, as dopamine agonists can have effects on cardiac function and vascular tone. While pergolide is not specifically contraindicated in cardiac patients, horses with significant heart disease should be monitored more closely when initiating treatment. The veterinarian should be informed of any known cardiac conditions when discussing PPID treatment options for an affected horse.

Pregnancy presents a relative contraindication to pergolide use, as the medication's effects on prolactin secretion could theoretically affect lactation and maternal-fetal interactions. While PPID is uncommon in mares of breeding age, it can occur, and treatment decisions for pregnant mares should involve careful discussion with a veterinarian about the relative risks of treated versus untreated PPID during pregnancy. The safety of pergolide during pregnancy and lactation has not been established through controlled studies in horses.

Caution is warranted when using pergolide in horses with a history of severe adverse reactions to the medication, even if these reactions did not constitute true hypersensitivity. Some horses are more sensitive to pergolide's effects and may experience pronounced appetite suppression, depression, or other symptoms at doses that other horses tolerate without difficulty. These horses may still benefit from pergolide treatment but may require lower doses, slower titration, or more intensive monitoring.

Pergolide has relatively few clinically significant drug interactions in horses, making it relatively straightforward to incorporate into treatment protocols for horses that may be receiving other medications. However, certain combinations warrant awareness and potential adjustment, and communication with your veterinarian about all medications your horse receives helps ensure safe and effective therapy.

Dopamine antagonists, including certain sedatives and tranquilizers such as acepromazine, have the potential to interfere with pergolide's mechanism of action. These medications block dopamine receptors, potentially reducing the effectiveness of pergolide, which works by stimulating these same receptors. While occasional use of dopamine-blocking sedatives for procedures is unlikely to significantly impact PPID control, frequent or regular use of these agents should be discussed with your veterinarian. Alternative sedation protocols may be preferred for horses receiving pergolide therapy.

The combination of pergolide with cyproheptadine is intentional when used for PPID management, representing adjunctive therapy rather than a concerning drug interaction. These medications work through different mechanisms (dopamine agonism versus serotonin antagonism) and may provide additive benefit in horses that do not respond adequately to pergolide alone. When this combination is used, appropriate monitoring for cumulative effects is important, but the interaction is therapeutic rather than problematic.

Metoclopramide, a prokinetic medication sometimes used in horses for gastrointestinal motility disorders, is a dopamine antagonist that could theoretically interfere with pergolide effectiveness. While metoclopramide is not commonly used in horses, awareness of this potential interaction is important if gastrointestinal issues requiring prokinetic therapy arise in a horse receiving pergolide for PPID. Alternative prokinetic options that do not block dopamine receptors may be preferred.

For competition horses, pergolide is a prohibited substance under FEI, USEF, and racing commission rules. The detection time for pergolide is not well characterized in horses, and conservative withdrawal periods should be discussed with your veterinarian if a horse receiving pergolide needs to compete. Given that PPID primarily affects older horses, many are not in competitive careers, but those that are require careful attention to drug rules and may need to have treatment modified or suspended around competition periods.

Regular monitoring of ACTH levels is essential for optimal PPID management in horses receiving pergolide. Baseline ACTH should be measured before starting treatment to confirm diagnosis and provide reference values. Follow-up testing, typically 4 to 6 weeks after starting treatment or adjusting doses, helps assess response and guide further dosing decisions. Stable patients on established doses typically require monitoring every 6 to 12 months, with more frequent testing during autumn when seasonal ACTH rise can complicate interpretation. Your veterinarian will advise on appropriate testing schedules based on your horse's specific situation.

Seasonal variation in ACTH levels presents a monitoring challenge that requires awareness. ACTH naturally rises in autumn (typically August through November in the Northern Hemisphere) in all horses, with particularly pronounced increases in horses with PPID. This seasonal rise can mask treatment response or suggest loss of control when the horse is actually adequately managed. Using seasonally adjusted reference ranges and timing monitoring appropriately helps avoid misinterpretation of results and unnecessary dose changes.

Special populations requiring additional attention include very elderly horses, those with severe disease, and horses with concurrent medical conditions. Elderly horses may be more sensitive to pergolide's effects and may benefit from slower dose titration. Horses with severe or advanced PPID may require higher doses and more intensive monitoring. Those with concurrent conditions such as liver or kidney disease may metabolize and excrete the medication differently, potentially requiring dose adjustment.

Competition considerations are critical for horses actively competing under FEI, USEF, or racing commission jurisdiction. Pergolide is classified as a prohibited substance, and detection in blood or urine samples results in rule violations regardless of therapeutic intent. Detection times are not well established, but pergolide may be detectable for extended periods after administration. Horses with PPID that must compete require careful discussion with veterinarians about management strategies, which may include alternative timing of competition or temporary treatment modifications.

Long-term management of horses on pergolide requires recognition that PPID is progressive despite treatment. Most horses require dose increases over time as the neurodegenerative process continues, and clinical signs that were initially well controlled may recur, indicating the need for dose adjustment. Regular veterinary evaluation, ongoing monitoring of clinical signs and laboratory values, and adjustment of therapy as needed are essential components of successful long-term PPID management.

Prascend tablets should be stored at controlled room temperature between 68 and 77 degrees Fahrenheit (20-25°C), with excursions permitted to 59-86°F (15-30°C). The medication should be kept in its original container with the lid tightly closed to protect from moisture and light. A climate-controlled tack room, medicine cabinet, or household location away from extreme temperatures provides appropriate storage. Avoid storing in hot barns during summer, unheated spaces during winter, or locations subject to direct sunlight or high humidity.

The tablets are sensitive to moisture and should not be exposed to wet conditions. If tablets become wet, discolored, or appear deteriorated, they should be discarded rather than administered. When handling tablets for administration, ensure that hands are dry, and work in a dry area of the barn. If dissolving tablets in water for syringe administration, prepare the solution immediately before dosing rather than mixing in advance and storing.

Handling precautions for humans working with pergolide include avoiding prolonged or repeated skin contact, particularly for pregnant women or those trying to conceive. Pergolide can be absorbed through the skin, and as a dopamine agonist, it could potentially affect human reproductive hormones. Washing hands after handling tablets is prudent, and those who must handle the medication frequently may wish to use gloves. Accidental ingestion by humans would require medical attention due to the medication's effects on dopamine pathways.

Disposal of unused or expired Prascend tablets should follow guidelines for pharmaceutical waste. Do not flush tablets down drains or discard in regular trash where environmental contamination or accidental exposure to other animals could occur. Many veterinary clinics and pharmacies accept unused medications for proper disposal, and community drug take-back programs provide another option. Proper disposal protects both the environment and prevents potential accidental exposure.

Draft horses with PPID require higher absolute doses of pergolide due to their greater body weight, though the dose per kilogram remains similar to lighter breeds. A draft horse weighing 900 kg would start at approximately 1.8 mg daily (typically rounded to 2 mg, or two tablets) compared to 1 mg for a 500 kg light horse. These larger doses may need to be divided or administered using methods that ensure complete consumption. Monitoring response and adjusting doses based on clinical signs and ACTH levels follows the same principles as for lighter breeds.

Ponies and miniature horses present the opposite challenge, requiring precise dosing at lower absolute amounts. A 250 kg pony would start at 0.5 mg daily (half a tablet), and smaller ponies or miniature horses may require even less. The scored Prascend tablets facilitate these lower doses, but careful attention to accurate dosing is important in small equids. Additionally, ponies are frequently affected by concurrent equine metabolic syndrome, which complicates PPID management and requires attention to diet and insulin status alongside pergolide therapy.

Morgan horses have been reported in some studies to have higher incidence of PPID compared to other breeds, meaning owners and veterinarians managing Morgan horses should maintain awareness of this predisposition as horses age. Early recognition and treatment of PPID in this breed may help prevent complications such as laminitis that can significantly impact quality of life. The approach to pergolide therapy does not differ from other breeds, but awareness of increased risk supports appropriate monitoring.

Quarter Horses, particularly those with the HYPP (hyperkalemic periodic paralysis) genetic condition, require attention to overall metabolic management when being treated for PPID. While HYPP does not directly affect pergolide therapy, the metabolic complexity of managing horses with multiple endocrine or metabolic conditions requires comprehensive treatment planning. Similarly, horses of any breed with concurrent equine metabolic syndrome require attention to insulin dysregulation alongside PPID management.

Cyproheptadine represents the primary adjunctive medication used alongside pergolide when first-line therapy alone provides inadequate PPID control. This antihistamine and serotonin antagonist works through different mechanisms than pergolide, potentially providing additive benefit through complementary pathways affecting pituitary function. When horses do not respond adequately to optimized pergolide doses, adding cyproheptadine is often the next step before considering the disease refractory to medical management.

Before Prascend received FDA approval, compounded pergolide was used for PPID treatment in horses, and compounded formulations remain available from veterinary compounding pharmacies. However, the FDA-approved product is preferred due to its demonstrated bioavailability, consistent quality, and known dose-response characteristics. Compounded pergolide may vary in potency and bioavailability between preparations and between batches from the same pharmacy, potentially affecting treatment consistency.

Supportive therapies for horses with PPID complement pergolide treatment and contribute importantly to overall management. These include hoof care and laminitis prevention strategies, dietary management appropriate for metabolic compromise (low-sugar, low-starch feeds), body clipping for horses with severe hirsutism, dental care important in geriatric horses, vaccination and parasite control considering potentially compromised immune function, and prompt treatment of secondary infections. Comprehensive PPID management integrates pergolide therapy with these supportive measures for optimal outcomes.

Levothyroxine is sometimes used in horses with PPID, particularly those with concurrent metabolic syndrome or obesity, though its role is for metabolic support rather than direct treatment of PPID. The relationship between thyroid function and PPID is complex, and levothyroxine supplementation in this context requires veterinary guidance regarding indication, dosing, and monitoring.